Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cytoprotection for Acute Ischemic Stroke: Critical Appraisal of Recent Clinical Trials.

Created on 27 Oct 2026

Authors

Johannes Boltze, Magdy H Selim, Ajay K Wakhloo, Marc Fisher

Published in

Stroke. Volume 57. Issue 11. Pages 3475-3480. Epub Oct 26, 2026.

Abstract

Several phase III clinical trials testing cytoprotective approaches have recently been completed, and many of these studies report a clinical benefit. Reviewing the outcomes of these trials in light of their specific designs reveals intriguing results. Trials designed with shorter treatment time windows (≤24 hours) and featuring high rates of recanalization therapies predominantly show neutral outcomes, that is, no therapeutic benefit. Studies using later time points (>24 hours to 14 days) and often enrolling patients in whom recanalization is not or only infrequently established show clear treatment effects. These results challenge our current understanding of cytoprotective approaches, which are believed to primarily target the penumbra as the key to therapeutic success. The reasons for this are unclear. They may include other, potentially unknown mechanisms of action that improve clinical outcome even when applied within longer time windows rather than exerting acute cytoprotection. Here, we discuss such potential mechanisms, to what extent they could explain the results of recent cytoprotection trials, and review consequences for future translational and clinical research.

PMID:
42932404
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement